September 28th, 2023Park City, Utah USA, September 28, 2023 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for patients with Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI), Coronary Artery Disease (CAD), and End Stage Renal Disease (ESRD), has successfully completed its Series B funding round....
May 18th, 2023Transit Scientific awarded increased U.S. patent protection for their novel exoskeleton focal-force angioplasty technology for use with standard off-the-shelf peripheral transluminal angioplasty (PTA) balloons.
Park City, Utah USA, May 18, 2023. Transit Scientific, a Utah-based medical device company, today announced newly issued...
August 15th, 2022Transit Scientific achieved increased U.S. patent protection for their novel exoskeleton focal-force angioplasty technology using standard off-the-shelf peripheral transluminal angioplasty (PTA) balloons.
Park City, Utah USA, August 15, 2022. Transit Scientific, a Utah-based medical device company, today announced additional U.S. patent...
June 27th, 2022Transit Scientific achieved increased U.S. patent protection for their novel exoskeleton focal-force angioplasty technology using standard off-the-shelf peripheral transluminal angioplasty (PTA) balloons.
Park City, Utah USA, June 27, 2022. Transit Scientific, a Utah-based medical device company, today announced newly issued U.S. patent...
